CP-690: Final Phase IIb data

Final data from a double-blind Phase II trial (Study A3921025) in 507 patients showed that 3, 10 and 15 mg twice-daily and 20 mg once-daily CP-690,550 plus methotrexate significantly improved ACR20 at...